Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyPediatric Oncology and HematologySolid TumorsProtocol groupBrain Tumors (ped.)Neuro-OncologyRadiotherapyDiseaseGliomaSubgroupBRAF mutationEpendymomaH3 K27M-MutationHER2+IDH1-MutationIDH2-MutationWHO grade 1 and 2WHO Grade 2WHO grade 2 and 3WHO Grade 3ICD10C71.-MeSHAstrocytomaEpendymomaGliomaOligodendrogliomaOptic Nerve GliomaSequenceTMZL75/Radiation, Glioma, C1 (PID1452) -|- C2 (PID1453) -|- C3-13 (PID1454)ChemotherapyChemo-substanceDordavipronLomustineProcarbazineTemozolomideTioguaninTovorafenibTrastuzumab DeruxtecanVincristineVorasidenibChemo-substanceDordavipronLomustineProcarbazineTemozolomideTioguaninTovorafenibTrastuzumab DeruxtecanVincristineVorasidenibChemo-substanceDordavipronLomustineProcarbazineTemozolomideTioguaninTovorafenibTrastuzumab DeruxtecanVincristineVorasidenibChemo-substanceDordavipronLomustineProcarbazineTemozolomideTioguaninTovorafenibTrastuzumab DeruxtecanVincristineVorasidenibNo. Substances134 RadiotherapySupportive therapySupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPegfilgrastimSupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPegfilgrastimSupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPegfilgrastimSupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPegfilgrastimNo. Substances234Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlAstheniaBleedingConstipationCOVID-19 infectionDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHeadacheHepatotoxicityIncrease AminotransferasesInfectionsLeukopeniaLymphopeniaNeutropeniaPruritusPyrexiaRashSeizuresThrombocytopenia below 50 000/µl only studiesPublicationAuthorArrillaga-Romany I Ater JLBuckner JCKilburn LBKrex DMellinghoff IKvan den Bent MJ Wick WDiseaseAnaplastisches Ependymom, wiederkehrend, HER2 aktiviertDiffuses Gliom, H3 K27M-mutiert, Karnofsky-Score mindestens 60, mindestens 90 Tage nach RadiatioGliom (Oligodendrogliom oder Astrozytom) WHO Grad 2, residuelle Krankheit, oder RezidivGliome WHO-Grad 2, Erstlinie, ECOG 0-2Neu diagnostiziertes, nicht 1p/19q kodeletiertes anaplastisches Gliom WHO Grad 2 oder 3, ECOG 0-2Neu diagnostiziertes anaplastisches Gliom, Grad 3, ErstlinieProgressives oder residuelles Low-Grade Gliom bei Kindern, WHO Grad 1+ 2, Alter unter 10, ErstliniePädiatrisches Low-Grade-Gliom (pLGG), 6 Monate bis 25 Jahren, rezidiviert/refraktär, aktivierende BRAF-AlterationOriginBrain Tumour Centre at Erasmus, Rotterdam, Netherlands, CATNON trial (EORTC study 26053-22054)Children's National Hospital, Washington, DC, USA, FIREFLY-1 trialDepartment of Neurology Clinic, University of Heidelberg, NOA-04Department of Neurosurgery, Technische Universität Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, GermanyMassachusetts General Hospital, Boston, MAMayo Clinic, Rochester, USAMemorial Sloan Kettering Cancer Center, New York, INDIGO trialUniversity of Texas MD Anderson Cancer Center, Houston, COG StudieProtokolle in Überarbeitung 10 protocols foundDordaviprone 625, Glioma (PID3177 V1.0)Lomustine 110 / Vincristine 2 / Procarbazine 60 / Radiation, Glioma (PID1694 V1.2)Lomustine 110 / Vincristine 2 / Procarbazine 60, Glioma (PID1347 V1.3)Temozolomide 150, Glioma, cycle 2 (PID1453 V1.2)Temozolomide 200, Glioma, Cycle 3-13 (PID1454 V1.2)Temozolomide 75 / Radiation, Glioma, Cycle 1 (PID1452 V1.2)Tioguanin 30 / Procarbazine 50 / Lomustine 110 / Vincristine 1.5, Glioma (PID604 V1.1)Tovorafenib 380, Glioma (PID3274 V1.0)Trastuzumab Deruxtecan 5,4, Ependymoma (PID3270 V1.0)Vorasidenib 40, Glioma (PID2819 V1.0)
